RxDoctor Payments Data

Alisha Fangmeyer, APRN

Family · Superior, NENPI 1568756609

Payments from drug & device makers

$2,135in general payments, 2019–2025

Across 140 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$538
  • Amgen$517
  • Novo Nordisk$301
  • Otsuka America Pharmaceutical, Inc.$297
  • Gilead$95
  • Astellas Pharma US Inc$80
  • plus $307 from 8 others

What the payments were for

  • Food & beverage$2,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,135 in reported general payments places this provider in the 85th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,495
Medicare patients
13
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$45,950
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,821
OzempicSemaglutide26$23,701
JardianceEmpagliflozin31$20,612
TradjentaLinagliptin19$13,335
TrulicityDulaglutide14$12,857
RybelsusSemaglutide13$11,847
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$8,792
MyrbetriqMirabegron17$7,545
XareltoRivaroxaban13$6,768
AbrysvoRsv Vacc, Pref A And Pref B/Pf20$6,427
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$6,426
FarxigaDapagliflozin Propanediol11$6,119
LivaloPitavastatin Calcium13$4,266
SymbicortBudesonide/Formoterol Fumarate12$3,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$55$52,37796 claims
Novo NordiskOzempic, Rybelsus$301$35,54839 claims
Lilly USA, LLCTrulicity$60$12,85714 claims
Astellas Pharma US IncMyrbetriq$80$7,54517 claims
Johnson & JohnsonXarelto$32$6,76813 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$4,26613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Nebraska.

Other family in Superior

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →